{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:38:40Z","timestamp":1789195120496,"version":"build-2803163510"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI110271"],"award-info":[{"award-number":["R01AI110271"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R38HL143581"],"award-info":[{"award-number":["R38HL143581"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AI145806"],"award-info":[{"award-number":["K24AI145806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI027763"],"award-info":[{"award-number":["P30 AI027763"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite early antiretroviral therapy (ART), ART-suppressed people with human immunodeficiency virus (HIV) (PWH) remain at higher risk for infections and infection-related cancers than the general population. The immunologic pathways that remain abnormal in this setting, potentially contributing to these complications, are unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ART-suppressed PWH and HIV-negative controls, all cytomegalovirus seropositive and enriched for HIV risk factors, were sampled from an influenza vaccine responsiveness study. PWH were stratified by timing of ART initiation (within 6 months of infection [early ART] vs later) and nadir CD4+ T-cell count among later initiators. Between-group differences in kynurenine-tryptophan (KT) ratio, interferon-inducible protein 10, soluble CD14 and CD163, soluble tumor necrosis factor receptor 2, interleukin 6, and soluble urokinase plasminogen activator receptor were assessed after confounder adjustment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most participants (92%) were male, reflecting the demographics of early-ART initiators in San Francisco. Most biomarkers were higher among later-ART initiators. Participants in the early-ART group achieved near-normal soluble tumor necrosis factor receptor 2, interleukin 6, and soluble urokinase plasminogen activator receptor levels, but substantially higher KT ratio than those without HIV after confounder adjustment (P\u2005=\u2005.008). Soluble CD14, soluble CD163, and interferon-inducible protein 10 trended similarly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While early-ART initiators restore near-normal levels of many inflammatory markers, the kynurenine pathway of tryptophan catabolism remains abnormally high. Because this pathway confers adaptive immune defects and predicts tuberculosis and cancer progression, this it may contribute to persistent risks of these complications in this setting.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiaa580","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T19:10:32Z","timestamp":1599592232000},"page":"1621-1630","source":"Crossref","is-referenced-by-count":29,"title":["Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus"],"prefix":"10.1093","volume":"223","author":[{"given":"Samuel R","family":"Schnittman","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia N","family":"Deitchman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Beck-Engeser","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaeLee","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa A","family":"York","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hartig","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick M","family":"Hecht","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Deeks","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca T","family":"Aweeka","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"},{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"2021052019531005500_CIT0001","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"2021052019531005500_CIT0002","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"2021052019531005500_CIT0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/cid\/ciz728","article-title":"Incidence and risk factors for invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus-infected individuals in a high-income setting","volume":"71","author":"Garcia Garrido","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021052019531005500_CIT0004","doi-asserted-by":"crossref","first-page":"e34156","DOI":"10.1371\/journal.pone.0034156","article-title":"Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community","volume":"7","author":"Gupta","year":"2012","journal-title":"PLoS One"},{"key":"2021052019531005500_CIT0005","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"Kuller","year":"2008","journal-title":"PLoS Med"},{"key":"2021052019531005500_CIT0006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0007","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1089\/aid.2016.0007","article-title":"Unchanged levels of soluble CD14 and IL-6 over time predict serious non-AIDS events in HIV-1-infected people","volume":"32","author":"Sunil","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021052019531005500_CIT0008","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0009","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/infdis\/jix113","article-title":"Immunologic pathways that predict mortality in HIV-infected Ugandans initiating antiretroviral therapy","volume":"215","author":"Lee","year":"2017","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0011","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/infdis\/jir134","article-title":"Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death","volume":"203","author":"Boulware","year":"2011","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0012","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0013","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/infdis\/jiw263","article-title":"Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals","volume":"214","author":"Knudsen","year":"2016","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0014","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","article-title":"Immunologic biomarkers, morbidity, and mortality in treated HIV infection","volume":"214","author":"Hunt","year":"2016","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0015","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2352-3018(15)00077-6","article-title":"Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study","volume":"2","author":"Rasmussen","year":"2015","journal-title":"Lancet HIV"},{"key":"2021052019531005500_CIT0016","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/QAD.0000000000001778","article-title":"No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts","volume":"32","author":"Wright","year":"2018","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0017","doi-asserted-by":"crossref","first-page":"e004987","DOI":"10.1161\/JAHA.116.004987","article-title":"Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) Trial","volume":"6","author":"Baker","year":".","journal-title":"J Am Heart Assoc"},{"key":"2021052019531005500_CIT0018","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S2213-2600(16)30319-8","article-title":"Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial","volume":"4","author":"Kunisaki","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2021052019531005500_CIT0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/cid\/ciw683","article-title":"Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection","volume":"64","author":"Sereti","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021052019531005500_CIT0020","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/infdis\/jiz030","article-title":"Very early initiation of antiretroviral therapy during acute HIV infection is associated with normalized levels of immune activation markers in cerebrospinal fluid but not in plasma","volume":"220","author":"Hellmuth","year":"2019","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/infdis\/jiv004","article-title":"Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals","volume":"212","author":"Hileman","year":"2015","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0022","doi-asserted-by":"crossref","first-page":"e55038","DOI":"10.1371\/journal.pone.0055038","article-title":"Kinetics of microbial translocation markers in patients on efavirenz or lopinavir\/r based antiretroviral therapy","volume":"8","author":"Vesterbacka","year":"2013","journal-title":"PLoS One"},{"key":"2021052019531005500_CIT0023","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/QAD.0000000000000988","article-title":"A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus","volume":"30","author":"Thompson","year":"2016","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0024","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/QAI.0000000000002079","article-title":"Immunological and neurometabolite changes associated with switch from efavirenz to an integrase inhibitor","volume":"81","author":"Asundi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021052019531005500_CIT0025","doi-asserted-by":"crossref","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"2021052019531005500_CIT0026","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/QAD.0000000000002190","article-title":"A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results","volume":"33","author":"Pilcher","year":"2019","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0027","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/cix550","article-title":"Plasma indoleamine 2, 3-dioxygenase, a biomarker for tuberculosis in human immunodeficiency virus-infected patients","volume":"65","author":"Adu-Gyamfi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021052019531005500_CIT0028","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/infdis\/jiu115","article-title":"The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy","volume":"210","author":"Byakwaga","year":"2014","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0029","doi-asserted-by":"crossref","first-page":"32ra6","DOI":"10.1126\/scitranslmed.3000632","article-title":"Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease","volume":"2","author":"Favre","year":"2010","journal-title":"Sci Transl Med"},{"key":"2021052019531005500_CIT0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/QAD.0000000000001432","article-title":"Soluble CD163 predicts incident chronic lung, kidney and liver disease in HIV infection","volume":"31","author":"Kirkegaard-Klitbo","year":"2017","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0031","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/infdis\/jir214","article-title":"Soluble CD163 made by monocyte\/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy","volume":"204","author":"Burdo","year":"2011","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0032","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/ciy966","article-title":"Soluble urokinase plasminogen activator receptor is predictive of non-AIDS events during antiretroviral therapy-mediated viral suppression","volume":"69","author":"Hoenigl","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021052019531005500_CIT0033","doi-asserted-by":"crossref","first-page":"ofw278","DOI":"10.1093\/ofid\/ofw278","article-title":"A randomized placebo controlled trial of aspirin effects on immune activation in chronically human immunodeficiency virus-infected adults on virologically suppressive antiretroviral therapy","volume":"4","author":"O\u2019Brien","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021052019531005500_CIT0034","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy","volume":"187","author":"Hunt","year":"2003","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0035","doi-asserted-by":"crossref","first-page":"e0144317","DOI":"10.1371\/journal.pone.0144317","article-title":"Late Antiretroviral Therapy (ART) initiation is associated with long-term persistence of systemic inflammation and metabolic abnormalities","volume":"10","author":"Ghislain","year":"2015","journal-title":"PLoS One"},{"key":"2021052019531005500_CIT0036","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/infdis\/jir507","article-title":"Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells","volume":"204","author":"Lederman","year":"2011","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0037","first-page":"Abstract 240","article-title":"Long-term elevated IL-6 and D-dimer after delayed art initiation in the start trial","volume-title":"2020 Conference on Retroviruses and Opportunistic Infections","author":"Baker"},{"key":"2021052019531005500_CIT0038","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jir520","article-title":"Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients","volume":"204","author":"Burdo","year":"2011","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0039","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2012.6698","article-title":"Arterial inflammation in patients with HIV","volume":"308","author":"Subramanian","year":"2012","journal-title":"JAMA"},{"key":"2021052019531005500_CIT0040","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/QAD.0b013e32836010bd","article-title":"Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection","volume":"27","author":"Burdo","year":"2013","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0041","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/QAI.0b013e3182237e54","article-title":"Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection","volume":"57","author":"Lyons","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021052019531005500_CIT0042","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/infdis\/jiw506","article-title":"Monocyte activation is associated with worse cognitive performance in HIV-infected women with virologic suppression","volume":"215","author":"Imp","year":"2017","journal-title":"J Infect Dis"},{"key":"2021052019531005500_CIT0043","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1378\/chest.14-0543","article-title":"Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4","volume":"146","author":"Attia","year":"2014","journal-title":"Chest"},{"key":"2021052019531005500_CIT0044","doi-asserted-by":"crossref","first-page":"e12756","DOI":"10.14814\/phy2.12756","article-title":"Widespread activation of immunity and pro-inflammatory programs in peripheral blood leukocytes of HIV-infected patients with impaired lung gas exchange","volume":"4","author":"Crothers","year":"2016","journal-title":"Physiol Rep"},{"key":"2021052019531005500_CIT0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/QAI.0000000000001711","article-title":"Brief report: systemic inflammation, immune activation, and impaired lung function among people living with HIV in Rural Uganda","volume":"78","author":"North","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021052019531005500_CIT0046","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/QAD.0000000000001092","article-title":"Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons","volume":"30","author":"Fitzpatrick","year":"2016","journal-title":"AIDS"},{"key":"2021052019531005500_CIT0047","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/hiv.12368","article-title":"Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy","volume":"17","author":"Estrada","year":"2016","journal-title":"HIV Med"},{"key":"2021052019531005500_CIT0048","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0000000000000566","article-title":"Oxidized LDL levels are increased in HIV infection and may drive monocyte activation","volume":"69","author":"Zidar","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021052019531005500_CIT0049","volume-title":"Neuroprotective mechanisms of nevirapine and efavirenz in model of neurodegeneration","author":"Zheve","year":"2007"},{"key":"2021052019531005500_CIT0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13365-018-0688-3","article-title":"Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir","volume":"25","author":"Keegan","year":"2019","journal-title":"J Neurovirol"},{"key":"2021052019531005500_CIT0051","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12879-017-2456-z","article-title":"Tryptophan catabolism and immune activation in primary and chronic HIV infection","volume":"17","author":"Gelpi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2021052019531005500_CIT0052","article-title":"Impact of acute HIV infection and early antiretroviral therapy on the human gut microbiome","author":"Sortino","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021052019531005500_CIT0053","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/156800909790192374","article-title":"Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy","volume":"9","author":"Liu","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"2021052019531005500_CIT0054","doi-asserted-by":"crossref","first-page":"193ra91","DOI":"10.1126\/scitranslmed.3006438","article-title":"Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism","volume":"5","author":"Vujkovic-Cvijin","year":"2013","journal-title":"Sci Transl Med"},{"key":"2021052019531005500_CIT0055","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.immuni.2009.10.007","article-title":"Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis","volume":"31","author":"Desvignes","year":"2009","journal-title":"Immunity"},{"key":"2021052019531005500_CIT0056","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J Exp Med"},{"key":"2021052019531005500_CIT0057","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1073\/pnas.1711373114","article-title":"In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis","volume":"115","author":"Gautam","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021052019531005500_CIT0058","doi-asserted-by":"crossref","first-page":"e137131","DOI":"10.1172\/jci.insight.137131","article-title":"Tryptophan catabolism reflects disease activity in human tuberculosis","volume":"5","author":"Collins","year":"2020","journal-title":"JCI Insight"},{"key":"2021052019531005500_CIT0059","doi-asserted-by":"crossref","first-page":"e15510","DOI":"10.1371\/journal.pone.0015510","article-title":"Transmitted drug resistance in persons with acute\/early HIV-1 in San Francisco, 2002-2009","volume":"5","author":"Jain","year":"2010","journal-title":"PLoS One"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa580\/34167362\/jiaa580.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/9\/1621\/38017983\/jiaa580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/9\/1621\/38017983\/jiaa580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:16:48Z","timestamp":1668683808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/9\/1621\/5904261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,11]]},"published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa580","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,9,11]]}}}